Table 3.
Efficacy of Erlotinib as a First-Line Therapy for Advanced Pancreatic Cancer
| Erlotinib + Gemcitabine (n = 285) | Placebo + Gemcitabine (n = 284) | Hazard Ratio and/orPValue | |
|---|---|---|---|
| Median survival | 6.24 months | 5.91 months | HR = 0.82; P = 0.038 |
| 1-year survival | 23% | 17% | P = 0.023 |
| Median PFS | 3.75 months | 3.55 months | HR = 0.77; P = 0.004 |
| DCR | 59% | 49.4% | P = 0.036 |
| Analysis of survival by grade of skin rash | |||
| Median survival Grade 0 |
5.3 months |
N/A |
P = 0.037 |
| Grade 1 | 5.8 months | ||
| Grade 2+ | 10.5 months | ||
| 1-year survival Grade 0 |
16% |
N/A |
P < 0.001 |
| Grade 1 | 9% | ||
| Grade 2+ | 43% | ||
DCR = disease control rate (complete response + partial response + stable disease); N/A = not available; PFS = progression-free survival.